1. Uveitis in children
- Author
-
Sheila T. Angeles-Han and Consuelo Egla Rabinovich
- Subjects
Pathology ,medicine.medical_specialty ,Visual acuity ,Adolescent ,Treatment outcome ,Visual Acuity ,Severe disease ,Arthritis ,Aqueous humor ,Blood Sedimentation ,macromolecular substances ,Article ,Autoimmune Diseases ,Aqueous Humor ,Uveitis ,03 medical and health sciences ,0302 clinical medicine ,Rheumatology ,Adrenal Cortex Hormones ,Recurrence ,Risk Factors ,Humans ,Medicine ,Child ,Hla dr1 antigen ,HLA-B27 Antigen ,030203 arthritis & rheumatology ,Tumor Necrosis Factor-alpha ,business.industry ,S100 Proteins ,HLA-DR1 Antigen ,Refractory Disease ,medicine.disease ,Dermatology ,Arthritis, Juvenile ,Black or African American ,Methotrexate ,Treatment Outcome ,Antirheumatic Agents ,030221 ophthalmology & optometry ,medicine.symptom ,business ,HLA-DRB1 Chains - Abstract
The review provides updates on novel risk markers for the development of pediatric inflammatory uveitis and a severe disease course, on treatment of refractory disease, and on the measurement of visual outcomes.There are several new genetic markers, biomarkers, and clinical factors that may influence a child's uveitis disease course. It is important to identify children at risk for poor visual outcomes and who are refractory to traditional therapy. Racial disparities have recently been reported. We describe agents of potential benefit. In addition, we discuss the importance of patient reported outcomes in this population.Uveitis can lead to vision-threatening complications. Timely and aggressive treatment of children identified to be at risk for a severe uveitis course may lead to improved outcomes.
- Published
- 2016
- Full Text
- View/download PDF